General Toxicity Notes
Blood pressure is the best guide to dose and interval. Hypotensive effects magnified by natriuretic agents or sodium depletion. Can cause hyperkalemia, metabolic acidosis. Acute renal dysfunction with bilateral or transplant renal artery stenosis, low renal perfusion pressure.
Half-Life (Normalesrd) Hours
9.4/No data
Plasma Protein Binding %
95
Volume Of Distribution L/Kg
0.23
Dose For Normal Renal Function
80-320 mg q24h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, titrate, [D]
References
Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000; 14 Suppl 1: S73-86. [PMID: 10854085] / Mü ller P, Flesch G, de Gasparo M, Gasparini M, Howald H. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997; 52: 441-9. [PMID: 9342579] / Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998; 19: 237-44. [PMID: 9604123] / Tepel M, van der Giet M, Zidek W. Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes. Kidney Blood Press Res. 2001; 24: 71-4. [PMID: 11174010]